Effects of cytapheresis on tumor necrosis factor receptor and on expression of CD63 in myeloperoxidase-antineutrophil cytoplasmic autoantibody-associated vasculitis

Therapeutic Apheresis and Dialysis

Volumn 11, Issue 5, 2007, Pages 337-340

  Hasegawa, Midori ^a   Nishii, Chikako ^b   Kabutan, Nao ^b   Kato, Masao ^b   Ohashi, Atsushi ^c   Nakai, Shigeru ^a   Murakami, Kazutaka ^a   Tomita, Makoto ^a   Nabeshima, Kunihiro ^a   Hiki, Yoshiyuki ^a   Oshima, Hisaji ^a   Sugiyama, Satoshi ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY HOSPITAL   (Japan)

^c FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

CD63; Cytapheresis; Myeloperoxidase antineutrophil cytoplasmic autoantibody associated vasculitis; Tumor necrosis factor receptor

Indexed keywords

AUTOANTIBODY; CD63 ANTIGEN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTAPHERESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; MALE; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULITIS;

AGED; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIGENS, CD; CYTAPHERESIS; FEMALE; GRANULOCYTES; HUMANS; MALE; MIDDLE AGED; PEROXIDASE; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; VASCULITIS;

EID: 34548528346     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2007.00496.x     Document Type: Article

References (17)

1. Jennete JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an International Consensus Conference. Arthritis Rheum 1994 37 : 187 92.
2. Jenette JC, Xiao H, Falk RJ. Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol 2006 17 : 1235 42.
3. Xiao H, Heeringa P, Liu Z et al. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol 2005 167 : 39 45.
4. Hasegawa M, Ohashi A, Kabutan N et al. Cytapheresis for the treatment of myeloperoxidase antineutrophil cytoplasmic autoantibody- associated vasculitis: a pilot study of 21 patients. Ther Apher Dial 2006 G10 : 414 20.
5. Feldman M, Pusey CD. Is there a role for TNF-α in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases. J Am Soc Nephrol 2006 17 : 1243 52.
6. Kuijpers TW, van Tool ATJ, van derScool CE et al. Membrane surface antigen expression on neutrophils: a reappraisal of the use of surface markers for neutrophil activation. Blood 1991 78 : 1105 11.
7. Luqmani RA, Bacon PA, Moots RJ et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994 87 : 671 8.
8. Beutler B. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem 1988 57 : 505 18.
9. Talmadge JE, Hamblin P, Schneider M et al. Immunomodulatory properties of recombinant murine and human tumor necrosis factor. Cancer Res 1988 48 : 544 50.
10. Tracey KJ, Vlassara H, Cerami A. Cachectin/tumour necrosis factor. Lancet 1989 20 : 1122 6.
11. Tartaglia LA, Goeddel DP. Two TNF receptors. Immunol Today 1992 13 : 151 3.
12. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 1992 89 : 4845 9.
13. Arimura Y, Minoshima S, Kamiya Y et al. Serum myeloperoxidase and serum cytokines in anti-myeloperoxidase antibody-associated glomerulonephritis. Clin Nephrol 1993 40 : 256 64.
14. Huugen D, Xiao H, van Esch A et al. Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide. Role of tumor necrosis factor-α. Am J Pathol 2005 167 : 47 58.
15. Little MA, Bhangal G, Smyth CL et al. Therapeutic effect of anti-TNF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Nephrol 2006 17 : 160 9.
16. Booth A, Harper L, Hammad T et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004 15 : 717 21.
17. Menegazzi R, Cramer R, Patriarca P, Scheurich P, Dri P. Evidence that tumor necrosis factor α (TNF) -induced activation of neutrophil respiratory burst on biologic surface is mediated by the p55 TNF receptor. Blood 1994 84 : 287 93.